Regeneron Pharmaceuticals, INC

Regeneron Pharmaceuticals announced a 17% revenue increase to $4.3 billion in Q2 2026, driven by significant growth in key products like Dupixent, EYLEA HD, and Libtayo.

Regeneron Pharmaceuticals anticipates a pre-tax acquired in-process research and development charge of approximately $127 million for the second quarter of 2026, impacting net income per diluted share by an estimated $1.00.

Regeneron Pharmaceuticals announced a 19% revenue increase to $3.6 billion for Q1 2026, driven by strong Dupixent and EYLEA HD sales, alongside significant pipeline advancements and a new $3 billion share repurchase program.

Regeneron Pharmaceuticals anticipates a significant acquired in-process R&D charge impacting its first quarter 2026 earnings.

Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, highlighting significant growth in Dupixent and EYLEA HD sales alongside pipeline advancements.

Regeneron Pharmaceuticals provided a corporate update at the J.P. Morgan Healthcare Conference, detailing preliminary Q4 2025 financial impacts and a robust pipeline targeting significant market opportunities.

Regeneron Pharmaceuticals reports strong revenue growth driven by Dupixent and Eylea HD, despite a decline in Eylea sales and ongoing legal challenges.

Regeneron Pharmaceuticals reported a strong Q1 2026 with increased revenues driven by Dupixent and EYLEA HD, despite a decline in EYLEA sales.

Regeneron Pharmaceuticals reported increased net income and diluted EPS for Q3 2025, driven by strong Dupixent and Libtayo sales, despite a significant decline in EYLEA revenue and regulatory delays for EYLEA HD and Ordspono.

Regeneron Pharmaceuticals reported a modest increase in net income and diluted EPS for the first half of 2025, driven by strong collaboration revenue, despite a significant decline in U.S. EYLEA sales and multiple regulatory setbacks for key products.

Regeneron's Q1 2025 results show a slight revenue decrease year-over-year, with EYLEA HD growth partially offsetting EYLEA decline and Dupixent continuing its strong growth trajectory.

Regeneron's Q3 2024 results show significant revenue growth, driven by strong sales of EYLEA HD and Dupixent, alongside increased collaboration revenue.

Regeneron Pharmaceuticals reports increased net income and diluted EPS in 2025, driven by strong Dupixent sales, despite a significant decline in U.S. EYLEA revenue and ongoing regulatory and legal challenges.

Regeneron's 2024 10-K filing reveals a year of revenue growth, pipeline progress, and strategic collaborations, alongside ongoing legal and regulatory challenges.

Regeneron Pharmaceuticals' CEO and CFO have certified the accuracy and completeness of the company's 2023 annual report on Form 10-K, ensuring compliance with SEC regulations.

Kathryn Guarini, a Director of Regeneron Pharmaceuticals, Inc., sold 400 shares of common stock on August 10, 2026 for $800.00 per share.

Regeneron Pharmaceuticals Director Arthur F. Ryan reported the sale of common stock under a pre-arranged trading plan.

Regeneron Pharmaceuticals Director Arthur F. Ryan sold 100 shares of common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan.

A Regeneron Pharmaceuticals director exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals' SVP Controller, Jason Pitofsky, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals Director Arthur F. Ryan sold common stock totaling 90 shares on February 9, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals has scheduled its 2025 Annual Meeting for June 13, 2025, and is soliciting shareholder votes on key proposals, including the election of directors, ratification of the company's independent auditor, executive compensation, and amendments to the company's Certificate of Incorporation.

Regeneron Pharmaceuticals aims to enhance shareholder value through proposed governance changes, including board declassification and elimination of supermajority voting requirements.

Regeneron Pharmaceuticals has scheduled its annual shareholder meeting for June 14, 2024, and is soliciting votes on key proposals including the election of directors, ratification of auditors, and executive compensation.

Regeneron's 2024 proxy statement outlines the company's dedication to innovation, pipeline advancement, and corporate responsibility, reflecting a strong financial position and a commitment to shareholder value.

Regeneron Pharmaceuticals, Inc. reported 3 holdings worth $177.2M for the period ended June 30, 2026.

Regeneron Pharmaceuticals discloses its equity investment portfolio as of March 31, 2026, featuring holdings in Adicet Bio and Intellia Therapeutics.

Regeneron Pharmaceuticals, Inc. filed its Q4 2025 13F-HR report, revealing holdings primarily in Intellia Therapeutics and Adicet Bio totaling over $33.7 million.

Regeneron Pharmaceuticals, Inc. filed its Form 13F-HR, revealing its equity investment portfolio totaling over $700 million as of September 30, 2025.

Regeneron Pharmaceuticals, Inc. has filed its Form 13F-HR, revealing its equity holdings totaling over $1.48 billion across four biotechnology and pharmaceutical companies as of June 30, 2025.

Regeneron Pharmaceuticals' latest 13F filing discloses over $1.2 billion in managed equity holdings as of March 31, 2025, with a focus on biotechnology companies.

Vanguard Capital Management has reported a beneficial ownership of 7.37% in Regeneron Pharmaceuticals Inc., holding over 7.6 million shares as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Regeneron Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 7 to their Schedule 13G, reporting a 3.2% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of June 30, 2025.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of May 30, 2025.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of December 31, 2024.